These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
280 related articles for article (PubMed ID: 38069427)
1. Pharmacomicrobiomics and Drug-Infection Interactions: The Impact of Commensal, Symbiotic and Pathogenic Microorganisms on a Host Response to Drug Therapy. Torres-Carrillo N; Martínez-López E; Torres-Carrillo NM; López-Quintero A; Moreno-Ortiz JM; González-Mercado A; Gutiérrez-Hurtado IA Int J Mol Sci; 2023 Dec; 24(23):. PubMed ID: 38069427 [TBL] [Abstract][Full Text] [Related]
2. Drug pharmacomicrobiomics and toxicomicrobiomics: from scattered reports to systematic studies of drug-microbiome interactions. Aziz RK; Hegazy SM; Yasser R; Rizkallah MR; ElRakaiby MT Expert Opin Drug Metab Toxicol; 2018 Oct; 14(10):1043-1055. PubMed ID: 30269615 [TBL] [Abstract][Full Text] [Related]
3. Pharmacomicrobiomics: The Holy Grail to Variability in Drug Response? Sharma A; Buschmann MM; Gilbert JA Clin Pharmacol Ther; 2019 Aug; 106(2):317-328. PubMed ID: 30937887 [TBL] [Abstract][Full Text] [Related]
4. Pharmacomicrobiomics: a novel route towards personalized medicine? Doestzada M; Vila AV; Zhernakova A; Koonen DPY; Weersma RK; Touw DJ; Kuipers F; Wijmenga C; Fu J Protein Cell; 2018 May; 9(5):432-445. PubMed ID: 29705929 [TBL] [Abstract][Full Text] [Related]
5. Targeting the gut microbiome to control drug pharmacomicrobiomics: the next frontier in oral drug delivery. Kamath S; Stringer AM; Prestidge CA; Joyce P Expert Opin Drug Deliv; 2023; 20(10):1315-1331. PubMed ID: 37405390 [TBL] [Abstract][Full Text] [Related]
6. Pharmacomicrobiomics: the impact of human microbiome variations on systems pharmacology and personalized therapeutics. ElRakaiby M; Dutilh BE; Rizkallah MR; Boleij A; Cole JN; Aziz RK OMICS; 2014 Jul; 18(7):402-14. PubMed ID: 24785449 [TBL] [Abstract][Full Text] [Related]
7. Toxicomicrobiomics: The Human Microbiome vs. Pharmaceutical, Dietary, and Environmental Xenobiotics. Abdelsalam NA; Ramadan AT; ElRakaiby MT; Aziz RK Front Pharmacol; 2020; 11():390. PubMed ID: 32372951 [TBL] [Abstract][Full Text] [Related]
8. Principles and Terminology for Host-Microbiome-Drug Interactions. Heirali A; Moossavi S; Arrieta MC; Coburn B Open Forum Infect Dis; 2023 May; 10(5):ofad195. PubMed ID: 37180590 [TBL] [Abstract][Full Text] [Related]
9. Drug response in association with pharmacogenomics and pharmacomicrobiomics: towards a better personalized medicine. Hassan R; Allali I; Agamah FE; Elsheikh SSM; Thomford NE; Dandara C; Chimusa ER Brief Bioinform; 2021 Jul; 22(4):. PubMed ID: 33253350 [TBL] [Abstract][Full Text] [Related]
10. Pharmacomicrobiomics: Influence of gut microbiota on drug and xenobiotic metabolism. Dikeocha IJ; Al-Kabsi AM; Miftahussurur M; Alshawsh MA FASEB J; 2022 Jun; 36(6):e22350. PubMed ID: 35579628 [TBL] [Abstract][Full Text] [Related]
11. Interaction between drugs and the gut microbiome. Weersma RK; Zhernakova A; Fu J Gut; 2020 Aug; 69(8):1510-1519. PubMed ID: 32409589 [TBL] [Abstract][Full Text] [Related]
12. The Future of Microbiome-Based Therapeutics in Clinical Applications. Sharma A; Das P; Buschmann M; Gilbert JA Clin Pharmacol Ther; 2020 Jan; 107(1):123-128. PubMed ID: 31617205 [TBL] [Abstract][Full Text] [Related]
13. Bugs as Drugs: Understanding the Linkage between Gut Microbiota and Cancer Treatment. Rana D; Salave S; Perla A; Nadkarni A; Kolhe S; Jindal AB; Mandoli A; Dwivedi P; Benival D Curr Drug Targets; 2022; 23(9):869-888. PubMed ID: 35264088 [TBL] [Abstract][Full Text] [Related]
14. Pharmacomicrobiomics and type 2 diabetes mellitus: A novel perspective towards possible treatment. Jia L; Huang S; Sun B; Shang Y; Zhu C Front Endocrinol (Lausanne); 2023; 14():1149256. PubMed ID: 37033254 [TBL] [Abstract][Full Text] [Related]
16. Pharmacomicrobiomics: Exploiting the Drug-Microbiota Interactions in Antihypertensive Treatment. Chen HQ; Gong JY; Xing K; Liu MZ; Ren H; Luo JQ Front Med (Lausanne); 2021; 8():742394. PubMed ID: 35127738 [TBL] [Abstract][Full Text] [Related]
17. Pharmacomicrobiomics-Guided Precision Oncology: A New Frontier of P4 (Predictive, Personalized, Preventive, and Participatory) Medicine and Microbiome-Based Therapeutics. Arga KY; Attia H; Aziz RK OMICS; 2024 Jan; 28(1):5-7. PubMed ID: 38190279 [TBL] [Abstract][Full Text] [Related]
18. The Yin-Yang Pharmacomicrobiomics on Treatment Response in Inflammatory Arthritides: A Narrative Review. Peretti S; Torracchi S; Russo E; Bonomi F; Fiorentini E; Aoufy KE; Bruni C; Lepri G; Orlandi M; Chimenti MS; Guiducci S; Amedei A; Matucci-Cerinic M; Bellando Randone S Genes (Basel); 2022 Dec; 14(1):. PubMed ID: 36672830 [TBL] [Abstract][Full Text] [Related]
19. Pharmacomicrobiomics of cell-cycle specific anti-cancer drugs - is it a new perspective for personalized treatment of cancer patients? Kaźmierczak-Siedlecka K; Bulman N; Ulasiński P; Sobocki BK; Połom K; Marano L; Kalinowski L; Skonieczna-Żydecka K Gut Microbes; 2023 Dec; 15(2):2281017. PubMed ID: 37985748 [TBL] [Abstract][Full Text] [Related]
20. Microbiome as therapeutics in vesicular delivery. Singhvi G; Girdhar V; Patil S; Gupta G; Hansbro PM; Dua K Biomed Pharmacother; 2018 Aug; 104():738-741. PubMed ID: 29807223 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]